BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

IRBM Launches Advanced Functional Genomics Platform to Power Precision Target Discovery and Validation

IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Pl...

April 03, 2025 | News

Yingli Pharma Receives FDA Clearance to Launch Global Phase 3 Trial of Linperlisib for Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic...

April 02, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Luye Pharma’s Twice-Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Luye Pharma Group announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japa...

April 01, 2025 | News

IASO Bio Secures First Approval Outside Mainland China for Equecabtagene Autoleucel in Macau

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative ce...

March 31, 2025 | News

Langhua Pharmaceutical Receives FDA EIR Following Successful cGMP Inspection for the Fourth Time

Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP...

March 31, 2025 | News

CJ BIO’s BiomeNrich™ POST M005 Becomes First Akkermansia muciniphila-Based Ingredient to Gain FDA NDIN Acknowledgment

CJ BIO's BiomeNrich™ POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient Notification (NDIN) ...

March 28, 2025 | News

China’s Everest Gets FDA Clearance for First mRNA Cancer Vaccine EVM14

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer ...

March 25, 2025 | News

GSK’s Omjjara Receives Local Approval in Singapore for Myelofibrosis Patients with Moderate to Severe Anaemia

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib Nearly all myelof...

March 25, 2025 | News

Sermonix and Regor Therapeutics Forge Strategic Alliance to Advance Targeted Therapies for Metastatic Breast Cancer

Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mB...

March 25, 2025 | News

Syneron Bio Enters $3.5B Strategic Collaboration with AstraZeneca to Develop Novel Macrocyclic Peptide Therapies

Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical lead...

March 24, 2025 | News

VantAI Introduces Neo-1, the First Unified Model for De Novo Molecular Generation and Structure Prediction

Neo-1 is the first model to unify de novo molecular generation and atomic-level structure prediction in a single model, by generating latent representa...

March 24, 2025 | News

Shanghai Henlius Secures FDA Orphan Drug Designation for HLX22 in Gastric Cancer

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for...

March 20, 2025 | News

Telix and R2PHARMA Secure ANVISA Approval for Illuccix®, Expanding PSMA-PET Imaging in Brazil

Telix Pharmaceuticals Limited announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approv...

March 19, 2025 | News

Stay Connected